Wall Street analyst estimates for Bausch + Lomb Corporation (BLCO): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options.
Consensus price target
$20.83 (+4 % vs price $20.00)
between $16.00 and $24.00 · 5 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $5.5B | $5.5B – $5.6B | $0.79 | 8 |
| 2027E | $5.8B | $5.8B – $5.9B | $1.10 | 9 |
| 2028E | $6.1B | $6.0B – $6.3B | $1.46 | 5 |
Figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 8 |
| Hold | 8 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 17 |
| Avg rating (−2 sell to +2 buy) | 0.41 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-10-28 | $0.21 | ||
| 2026-07-29 | $0.16 | $0.15 | +3.6% |
| 2026-04-29 | $0.08 | $0.06 | +33.3% |
| 2026-02-18 | $0.32 | $0.35 | -8.6% |
| 2025-10-29 | $0.18 | $0.16 | +12.5% |
| 2025-07-30 | $0.07 | $0.06 | +16.7% |
| 2025-04-30 | $-0.07 | $0.03 | -333.3% |
| 2025-02-19 | $0.25 | $0.24 | +4.2% |
Valuation Ratios
| Price / Book | 1.11 |
| EV / EBITDA | 9.94 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.67B | $3.78B | $3.41B | $3.77B | $3.77B | $4.15B | $4.79B | $5.10B |
| Cost of Revenue | $1.31B | $1.33B | $1.28B | $1.47B | $1.52B | $1.64B | $1.87B | $2.31B |
| Gross Profit | $2.35B | $2.45B | $2.13B | $2.30B | $2.25B | $2.50B | $2.92B | $2.79B |
| Research & Development | $221.0M | $258.0M | $281.0M | $271.0M | $307.0M | $324.0M | $343.0M | $371.0M |
| Selling, General & Admin | $1.33B | $1.38B | $1.25B | $1.39B | $1.48B | $1.74B | $2.08B | $2.23B |
| Operating Expenses | $1.94B | $2.06B | $1.87B | $1.97B | $2.04B | $2.37B | $2.76B | $2.60B |
| Operating Income | $416.0M | $396.0M | $260.0M | $329.0M | $207.0M | $130.0M | $162.0M | $188.0M |
| EBITDA | $922.0M | $936.0M | $732.0M | $733.0M | $598.0M | $499.0M | $601.0M | $535.0M |
| Interest Expense | 0 | 0 | 0 | 0 | $146.0M | $283.0M | $399.0M | $431.0M |
| Pre-tax Income | $417.0M | $399.0M | $290.0M | $318.0M | $73.0M | -$166.0M | -$234.0M | -$317.0M |
| Income Tax | -$302.0M | $96.0M | $307.0M | $125.0M | $58.0M | $82.0M | $71.0M | $35.0M |
| Net Income | $710.0M | $298.0M | -$18.0M | $182.0M | $6.0M | -$260.0M | -$317.0M | -$360.0M |
| EPS | $2.03 | $0.85 | $-0.05 | $0.52 | $0.04 | $-0.74 | $-0.90 | $-1.02 |
| EPS (Diluted) | $2.03 | $0.85 | $-0.05 | $0.52 | $0.04 | $-0.74 | $-0.90 | $-1.02 |
| Shares Outstanding (Diluted) | 350.0 M | 350.0 M | 350.0 M | 350.0 M | 350.0 M | 350.5 M | 351.8 M | 353.8 M |
Price
| Price | $20.00 (closing price, October 30, 2026) |
| Market Cap | $7.1B |
| Exchange | NYSE |
| Country | CA |
Related companies: ARWR · PCVX · PTCT · TGTX · CRSP · MMSI · GKOS
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of BLCO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks